Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Lanreotide acetate
Drug ID BADD_D01244
Description Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured by the company, _Ipsen Pharmaceuticals_ as lanreotide acetate, and marketed as _Somatuline_. It is approved in several countries worldwide, including the United Kingdom, Australia, and Canada. Lanreotide was first approved for use in the United States by the FDA on August 30, 2007.
Indications and Usage Lanreotide is a somatostatin analog approved for treatment of neuroendocrine tumours and acromegaly.
Marketing Status approved
ATC Code H01CB03
DrugBank ID DB06791
KEGG ID D04666
MeSH ID C060347
PubChem ID 71349
TTD Drug ID D0M2YE
NDC Product Code 69097-880; 52076-6272; 69097-870; 71161-116; 15054-1090; 69097-890; 76282-710; 52076-6264; 76282-709; 35207-0011; 71161-114; 71161-115; 76282-711; 15054-1120; 32861-0006; 15054-1060
UNII IEU56G3J9C
Synonyms lanreotide | 3-(2-naphthyl)alanyl-cystinyl-tyrosyl-tryptophyl-lysyl-valyl-cystinyl-threonine amide | D-Nal-Cys-Tyr-Trp-Lys-Val-Cys-Thr-NH2 | angiopeptin | naphthalenyl-cyclo(cysteinyl-tyrosyl-tryptophyl-lysyl-valyl-cysteinyl)threoninamide | L-Threoninamide, 3-(2-naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-, cyclic (2-7)-disulfide | Nal-cyclo(Cys-Tyr-Trp-Lys-Val-Cys)-Thr-NH2 | Nal-cyclo(Cys-Tyr-Trp-Lys-Val-Cys)Thr-NH2 | 2-naphthylalanyl-cyclo(cysteinyl-tyrosyl-tryptophyl-lysyl-valyl-cysteinyl)-threoninamide | 3-(2-naphthyl)-D-Ala-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2 | naphthyl-cyclo(Cys-Tyr-Trp-Lys-Val-Cys)Thr-NH2 | BIM 23014 | BIM-23014 | DC 13-116 | DC13-116 | DC-13-116 | lanreotide acetate | Somatulina | Somatuline | lanreotide-SR | BIM 23014 C | BIM 23014C | BIM-23014 C | 188Re-lanreotide | Somatulin
Chemical Information
Molecular Formula C54H69N11O10S2
CAS Registry Number 108736-35-2
SMILES CC(C)C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC 4=CC=C(C=C4)O)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)N)C(=O)NC(C(C)O)C(=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Alopecia23.02.02.001--
Anaemia01.03.02.001--
Anaphylactic shock10.01.07.002; 24.06.02.004---
Angioedema10.01.05.009; 22.04.02.008; 23.04.01.001---
Anxiety19.06.02.002--
Aortic valve incompetence02.07.03.001---
Aortic valve stenosis02.07.03.004---
Arrhythmia supraventricular02.03.03.001---
Arthralgia15.01.02.001--
Asthenia08.01.01.001---
Atrial septal defect02.04.02.009; 03.07.02.002---
Atrioventricular block02.03.01.002---
Autonomic nervous system imbalance08.01.01.010; 17.05.01.011; 24.06.01.005---
Back pain15.03.04.005--
Bone pain15.02.01.001--
Bradycardia02.03.02.002---
Bronchitis11.01.09.001; 22.07.01.001--
Bundle branch block02.03.01.009---
Bursitis12.04.03.010; 15.04.01.001---
Cardiac murmur13.14.01.001---
Cardiomegaly02.04.02.001---
Cardiovascular disorder02.11.01.010; 24.03.02.009---
Cataract06.06.01.001--
Change of bowel habit07.02.03.002---
Chest pain02.02.02.011; 08.01.08.002; 22.12.02.003---
Cholecystitis09.03.01.001--
Cholelithiasis09.03.01.002---
Constipation07.02.02.001--
Corneal deposits06.06.03.002---
The 1th Page    1 2 3 4 5    Next   Last    Total 5 Pages